MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 200700 | Name: Celecoxib
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Celecoxib, also known as SC-58635 and YM-177, is a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID). It is used to treat the pain and inflammation of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain in adults, painful menstruation, and juvenile rheumatoid arthritis in people two years or older.

Chemical Structure

Celecoxib
Celecoxib
CAS#169590-42-5

Theoretical Analysis

MedKoo Cat#: 200700

Name: Celecoxib

CAS#: 169590-42-5

Chemical Formula: C17H14F3N3O2S

Exact Mass: 381.0759

Molecular Weight: 381.37

Elemental Analysis: C, 53.54; H, 3.70; F, 14.94; N, 11.02; O, 8.39; S, 8.41

Price and Availability

Size Price Availability Quantity
1g USD 150.00 2 weeks
2g USD 225.00 2 weeks
5g USD 450.00 2 weeks
10g USD 750.00 2 weeks
20g USD 1,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
SC-58635; SC 58635; SC58635; YM-177; YM 177; YM177. Celecoxib; brand name Celebrex; Xilebao.
IUPAC/Chemical Name
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
InChi Key
RZEKVGVHFLEQIL-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
SMILES Code
O=S(C1=CC=C(N2N=C(C(F)(F)F)C=C2C3=CC=C(C)C=C3)C=C1)(N)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>5 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Certificate of Analysis
View CoA: current batch, Lot#C9B07B26
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction
Biological target:
Celecoxib is a selective COX-2 inhibitor with an IC50 of 40 nM.
In vitro activity:
LPS (lipopolysaccharide) treatment for 24 and 48 h increased the viability of HSC-3 cells (P<0.01; Fig. 1A); whereas, celecoxib decreased cell viability in a dose- and time-dependent manner (P<0.01; Fig. 1B), indicating that the cells were sensitive to celecoxib. The proliferation of LPS-treated HSC-3 cells was significantly inhibited by treatment with celecoxib (100 µM for 48 h) (P<0.01; Fig. 1C). The protein expression levels of COX-2 and p53 with/without celecoxib treatment were also examined in HSC-3 cells via western blotting. Compared with untreated cells, treatment of HSC-3 cells with 100 µM celecoxib downregulated the protein expression levels of COX-2 after 12 h, but there was little change in p53 expression levels (Fig. 1D). The COX-2/β-actin ratios in the HSC-3 cells were significantly decreased by the celecoxib treatment (Fig. 1E). Reference: Oncol Lett. 2019 Dec; 18(6): 5793–5800. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865759/
In vivo activity:
To test the in vivo chemopreventive effect of metronomic Celecoxib on seeded cancer, this study implanted syngeneic HCC cells into bilateral flanks of C57BL/6 mice that were fed by either metronomic Celecoxib (n = 18 sites) or placebo (n = 16 sites) as protocol (Figure 1A). The bodyweight of both groups was comparable that may imply metronomic Celecoxib therapy did not impair the general physiologic status of mice (e.g., growth and intake) (Figure 1B). However, tumor size of implanted syngeneic HCC was significantly reduced in the “metronomic Celecoxib” group compared to the placebo group (tumor volume on post-implant day 37 [mean ± SEM] = 539.8 ± 135.8 mm3 vs. 1138.0 ± 175.0 mm3, P < 0.05) (Figures 1C, D). H&E stating at comparable-sized HCCs showed a significant central necrosis in the “metronomic Celecoxib” group compared to the placebo group (Figure 1E). Reference: Front Oncol. 2020; 10: 572861. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609882/
Solvent mg/mL mM
Solubility
DMSO 63.0 165.19
DMF 25.0 65.55
Ethanol 29.0 76.04
Ethanol:PBS (pH 7.2) (1:4) 0.2 0.52
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 381.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Yoshida H, Yoshimura H, Matsuda S, Yamamoto S, Ohmori M, Ohta K, Ryoke T, Itoi H, Kiyoshima T, Kobayashi M, Sano K. Celecoxib suppresses lipopolysaccharide-stimulated oral squamous cell carcinoma proliferation in vitro and in vivo. Oncol Lett. 2019 Dec;18(6):5793-5800. doi: 10.3892/ol.2019.10975. Epub 2019 Oct 10. PMID: 31788052; PMCID: PMC6865759. 2. Costela-Ruiz VJ, Melguizo-Rodríguez L, Illescas-Montes R, Ramos-Torrecillas J, Manzano-Moreno FJ, Ruiz C, Bertos EL. Effects of Therapeutic Doses of Celecoxib on Several Physiological Parameters of Cultured Human Osteoblasts. Int J Med Sci. 2019 Sep 20;16(11):1466-1472. doi: 10.7150/ijms.37857. PMID: 31673238; PMCID: PMC6818209. 3. Yeh CC, Liao PY, Pandey S, Yung SY, Lai HC, Jeng LB, Chang WC, Ma WL. Metronomic Celecoxib Therapy in Clinically Available Dosage Ablates Hepatocellular Carcinoma via Suppressing Cell Invasion, Growth, and Stemness in Pre-Clinical Models. Front Oncol. 2020 Oct 21;10:572861. doi: 10.3389/fonc.2020.572861. PMID: 33194674; PMCID: PMC7609882. 4. Ouyang N, Zhao Y, Chen Q, Chen L, Fang B, Dai J, Shen G. The effect of celecoxib in traumatic heterotopic ossification around temporomandibular joint in mice. Osteoarthritis Cartilage. 2020 Apr;28(4):502-515. doi: 10.1016/j.joca.2020.01.014. Epub 2020 Feb 14. PMID: 32061965.
In vitro protocol:
1. Yoshida H, Yoshimura H, Matsuda S, Yamamoto S, Ohmori M, Ohta K, Ryoke T, Itoi H, Kiyoshima T, Kobayashi M, Sano K. Celecoxib suppresses lipopolysaccharide-stimulated oral squamous cell carcinoma proliferation in vitro and in vivo. Oncol Lett. 2019 Dec;18(6):5793-5800. doi: 10.3892/ol.2019.10975. Epub 2019 Oct 10. PMID: 31788052; PMCID: PMC6865759. 2. Costela-Ruiz VJ, Melguizo-Rodríguez L, Illescas-Montes R, Ramos-Torrecillas J, Manzano-Moreno FJ, Ruiz C, Bertos EL. Effects of Therapeutic Doses of Celecoxib on Several Physiological Parameters of Cultured Human Osteoblasts. Int J Med Sci. 2019 Sep 20;16(11):1466-1472. doi: 10.7150/ijms.37857. PMID: 31673238; PMCID: PMC6818209.
In vivo protocol:
1. Yeh CC, Liao PY, Pandey S, Yung SY, Lai HC, Jeng LB, Chang WC, Ma WL. Metronomic Celecoxib Therapy in Clinically Available Dosage Ablates Hepatocellular Carcinoma via Suppressing Cell Invasion, Growth, and Stemness in Pre-Clinical Models. Front Oncol. 2020 Oct 21;10:572861. doi: 10.3389/fonc.2020.572861. PMID: 33194674; PMCID: PMC7609882. 2. Ouyang N, Zhao Y, Chen Q, Chen L, Fang B, Dai J, Shen G. The effect of celecoxib in traumatic heterotopic ossification around temporomandibular joint in mice. Osteoarthritis Cartilage. 2020 Apr;28(4):502-515. doi: 10.1016/j.joca.2020.01.014. Epub 2020 Feb 14. PMID: 32061965.
1: Dinh TN, Onea AS, Jazirehi AR. Combination of celecoxib (Celebrex(®)) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas. Am J Clin Exp Immunol. 2017 May 15;6(3):27-42. eCollection 2017. Review. PubMed PMID: 28804691; PubMed Central PMCID: PMC5545683. 2: Garner SE, Fidan D, Frankish RR, Judd M, Shea B, Towheed T, Tugwell P, Wells GA. WITHDRAWN: Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev. 2017 Jun 9;6:CD003831. doi: 10.1002/14651858.CD003831.pub2. Review. PubMed PMID: 28598564. 3: Fidahic M, Jelicic Kadic A, Radic M, Puljak L. Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev. 2017 Jun 9;6:CD012095. doi: 10.1002/14651858.CD012095.pub2. Review. PubMed PMID: 28597983. 4: Puljak L, Marin A, Vrdoljak D, Markotic F, Utrobicic A, Tugwell P. Celecoxib for osteoarthritis. Cochrane Database Syst Rev. 2017 May 22;5:CD009865. doi: 10.1002/14651858.CD009865.pub2. Review. PubMed PMID: 28530031. 5: Dean L. Celecoxib Therapy and CYP2C9 Genotype. 2016 Aug 18. In: Pratt V, McLeod H, Dean L, Malheiro A, Rubinstein W, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK379478/ PubMed PMID: 28520369. 6: Celecoxib safety revisited. Med Lett Drugs Ther. 2016 Dec 19;58(1510):159. Review. PubMed PMID: 27960193. 7: Marini S, De Berardis D, Vellante F, Santacroce R, Orsolini L, Valchera A, Girinelli G, Carano A, Fornaro M, Gambi F, Martinotti G, Di Giannantonio M. Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials. Mediators Inflamm. 2016;2016:3476240. doi: 10.1155/2016/3476240. Epub 2016 Jul 25. Review. PubMed PMID: 27524864; PubMed Central PMCID: PMC4976163. 8: Xu C, Gu K, Yasen Y, Hou Y. Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore). 2016 May;95(20):e3585. doi: 10.1097/MD.0000000000003585. Review. PubMed PMID: 27196460; PubMed Central PMCID: PMC4902402. 9: Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Survival Results From STAMPEDE (NCT00268476). Clin Adv Hematol Oncol. 2016 Apr;14(4 Suppl 5):11-3. Review. PubMed PMID: 27167844. 10: Papageorgiou N, Zacharia E, Briasoulis A, Charakida M, Tousoulis D. Celecoxib for the treatment of atherosclerosis. Expert Opin Investig Drugs. 2016;25(5):619-33. doi: 10.1517/13543784.2016.1161756. Epub 2016 Mar 21. Review. PubMed PMID: 26940257. 11: Khan JS, Margarido C, Devereaux PJ, Clarke H, McLellan A, Choi S. Preoperative celecoxib in noncardiac surgery: A systematic review and meta-analysis of randomised controlled trials. Eur J Anaesthesiol. 2016 Mar;33(3):204-14. doi: 10.1097/EJA.0000000000000346. Review. PubMed PMID: 26760402. 12: Hou LC, Huang F, Xu HB. Does celecoxib improve the efficacy of chemotherapy for advanced non-small cell lung cancer? Br J Clin Pharmacol. 2016 Jan;81(1):23-32. doi: 10.1111/bcp.12757. Epub 2015 Nov 2. Review. PubMed PMID: 26331772; PubMed Central PMCID: PMC4693572. 13: Chen J, Shen P, Zhang XC, Zhao MD, Zhang XG, Yang L. Efficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trials. Clin Ther. 2014 Aug 1;36(8):1253-63. doi: 10.1016/j.clinthera.2014.06.015. Epub 2014 Jul 10. Review. PubMed PMID: 25016505. 14: Faridhosseini F, Sadeghi R, Farid L, Pourgholami M. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum Psychopharmacol. 2014 May;29(3):216-23. doi: 10.1002/hup.2401. Epub 2014 Mar 16. Review. PubMed PMID: 24911574. 15: Frolov RV, Singh S. Celecoxib and ion channels: a story of unexpected discoveries. Eur J Pharmacol. 2014 May 5;730:61-71. doi: 10.1016/j.ejphar.2014.02.032. Epub 2014 Mar 11. Review. PubMed PMID: 24630832. 16: Scheinfeld N. Treatment of hidradenitis supprurativa associated pain with nonsteroidal anti-inflammatory drugs, acetaminophen, celecoxib, gabapentin, pegabalin, duloxetine, and venlafaxine. Dermatol Online J. 2013 Nov 15;19(11):20616. Review. PubMed PMID: 24314785. 17: Derry S, Moore RA. Single dose oral celecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2013 Oct 22;(10):CD004233. doi: 10.1002/14651858.CD004233.pub4. Review. PubMed PMID: 24150982. 18: Kumar V, Kaur K, Gupta GK, Gupta AK, Kumar S. Developments in synthesis of the anti-inflammatory drug, celecoxib: a review. Recent Pat Inflamm Allergy Drug Discov. 2013 May;7(2):124-34. Review. PubMed PMID: 23565678. 19: Huelin R, Pokora T, Foster TS, Mould JF. Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies. Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):505-23. doi: 10.1586/erp.12.36. Review. PubMed PMID: 22971036. 20: Derry S, Moore RA. Single dose oral celecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2012 Mar 14;(3):CD004233. doi: 10.1002/14651858.CD004233.pub3. Review. Update in: Cochrane Database Syst Rev. 2013;(10):CD004233. PubMed PMID: 22419293; PubMed Central PMCID: PMC4161494.

View History

SP27

SP27

Elsulfavirine sodium

Elsulfavirine sodium

Lemidosul

Lemidosul

GSK3008348E

GSK3008348E

SB711

SB711

Jun13728

Jun13728